1. Scrip
  2. >>Therapy Areas

Archimedes makes progress with novel drug delivery technology

 
• By Simon Varcoe

Archimedes Pharma has strengthened its portfolio with positive results in Phase I proof-of-concept studies of two intranasal development projects. The development adds to the strong outlook already created by its lead investigational product NasalFent (fentanyl citrate), which is due to be filed for approval in the first half of this year.

Archimedes Pharma has strengthened its portfolio with positive results in Phase I proof-of-concept studies of two intranasal development projects. The development adds to the strong outlook already created by its lead investigational product NasalFent (fentanyl citrate), which is due to be filed for approval in the first half of this year.

The private UK company's intranasal forms of apomorphine formulation (3.5mg doses) and diazepam (5mg doses) showed high bioavailability, positive pharmacokinetics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?